The overall results of vortioxetine on cognitive function in MDD patients subjectively reporting cognitive dysfunction could be better viewed in context with the treatment of cognitive functioning in patients with Alzheimer's disease, where the 1-year treatment effect of cholinesterase inhibitors results in a Cohen's d effect size ranging from 0.3 to 0.5 (Atri et al, 2008; Rockwood, 2004), despite a magnitude of disease impact several SD above the norm. Here, BCHE is linked to early-onset autosomal dominant Alzheimer disease.